RT Journal Article
ID 46fbf2231a6e1eab
A1 Boone, David N. 
A1 Lee, Adrian V. 
T1 Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling
JF Critical Reviews™ in Oncogenesis
JO CRO
YR 2012
FD 2012-03-29
VO 17
IS 2
SP 161
OP 173
K1 biomarkers
K1 IGF1
K1 targeted therapy
K1 neoplasia
K1 cancer
K1 insulin
K1 signaling
K1 signatures
AB Overwhelming evidence implicates insulin-like growth factor (IGF) signaling in the growth and survival of many types of human cancer cells. Numerous inhibitors of the IGF1 receptor (IGF1R) have been developed, and they displayed remarkable antineoplastic activity in preclinical models and promising success in early phase clinical trials. However, while responses have been observed in numerous cancer types, they have occurred in a minority of patients, and serious toxicities have been observed. Identifying patients likely to benefit from anti-IGF1R therapy requires further characterizing the role of IGF1 signaling in various stages of tumorigenesis in order to identify critical downstream factors that may be used as predictors of response, or to serve as novel therapeutic targets. Recent microarray analyses have begun to unravel expression "signatures" specific for IGF1 that correlate with poor breast cancer prognosis and with response to anti-IGFIR inhibitors. In this review we briefly discuss the history of the IGF1 family in neoplasia, how it is targeted, results from clinical trials, and the quest for biomarkers that will predict response to IGF1R-targeted therapy.
PB Begell House
LK https://www.dl.begellhouse.com/journals/439f422d0783386a,7edf95815057eb89,46fbf2231a6e1eab.html